Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper discusses the molecular basis of intestinal regeneration and highlights the potential role of echinoderms in enhancing regenerative biology research, but reports no new research findings.

This study found that arginine deficiency in androgenetic alopecia patients is linked to increased oxidative stress and impaired hair follicle regeneration, with targeted arginine supplementation showing promise as a therapeutic strategy.

This study found that 60% of examined prostate tumors had new somatic substitutions in the SRD5A2 gene, affecting enzyme activity and potentially influencing prostate cancer progression.

This piece reflects on the past year of editing the Assistants' Corner and presents no new research findings.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

This study found that a chemically modified small-interfering RNA candidate, AR-27 E-Chol, effectively stimulated hair regrowth and reduced androgen receptor gene expression in a mouse model of androgenetic alopecia, indicating its potential as a novel therapeutic approach.

This study found that specific residues in human steroid 5alpha-reductase types 1 and 2 influence substrate binding and resistance to the inhibitor Finasteride, with certain substitutions significantly affecting these interactions.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

Among participants in a 26-week trial, this study by REVIAN Inc. reported that their REVIAN RED dual wavelength LED light treatment for androgenetic alopecia was both safe and effective at the 16-week mark.

This abstract contains no study findings or conclusions.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

This report describes a novel AR gene mutation in a female patient, contributing to androgen insensitivity syndrome, and emphasizes its potential impact on genetic counseling.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This study found that AR-007 degrades faster and has a stronger association with hsp70 than AR-014, suggesting it is less stable when bound to the androgen receptor.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

This chapter reviews procedural hair restoration techniques, including platelet-rich plasma and hair transplantation, and reports no new clinical findings.

In this pilot study of Indonesians, the rs1998076 genetic variant was not significantly linked to androgenetic alopecia, though the GG genotype showed a non-significant trend toward higher odds, while clinical factors like age and hypertension were correlated with increased risk.

This study identified differences in adverse symptoms among patients with post-finasteride syndrome based on short and long androgen receptor gene polymorphisms.

This abstract reports funding sources for ongoing research and does not present any study results.

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

This study evaluated a chemically modified siRNA, AR-27 E-Chol, which effectively promoted hair regrowth and reduced androgen receptor gene expression in a DHT-induced mouse model of androgenetic alopecia, suggesting its potential as a novel therapeutic candidate.

This review discusses various herbal and pharmaceutical products, including their purported uses and possible interactions, but reports no new research findings.